Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - Vyant Bio, Inc.q12017exhibit322certificat.htm
EX-31.2 - EXHIBIT 31.2 - Vyant Bio, Inc.q12017exhibit312certificat.htm
EX-31.1 - EXHIBIT 31.1 - Vyant Bio, Inc.q12017exhibit311certificat.htm
EX-10.1 - EXHIBIT 10.1 - Vyant Bio, Inc.exh101shaknovich2017.htm
10-Q - 10-Q - Vyant Bio, Inc.a2017q1cgix-3312017x10q.htm


Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Cancer Genetics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Panna L. Sharma, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 12, 2017

 
/s/ Panna L. Sharma
Panna L. Sharma
President and Chief Executive Officer
(Principal Executive Officer)
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.